Blog | HemaCare

Developing Antibody Drugs Against B-cells

Jan 11, 2016 1:00:44 PM / by Daisy posted in Cancer Immunology, chronic lymphocytic leukemia, clinical trial, CLL, obinutuzumab, research, rituximab

0 Comments

The success of rituximab as an antibody drug targeting B-cells has led to the development of obinutuzumab – a similar, third-generation drug

Chronic lymphocytic leukemia (CLL) is a B-cell disease that is currently incurable. Combining targeted drugs has improved overall survival. However, not all patients benefit, because B-cells can harness any of several mechanisms to gain unrestricted proliferative capacity (see here).

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts